PharmaNutra SpA (PHN) AI Stock Analysis

• Market Cap: €453.55M
• Dividend Yield: 1.82%
• Average Volume (3M): 8.05K
• Price to Earnings (P/E): 27.4
• Beta (1Y): 0.50
• Revenue Growth: 17.78%
• EPS Growth: 63.72%
• Country: IT
• Employees: 118
• Sector: Healthcare
• Sector Strength: 44
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.25
• Shares Outstanding: 9,680,977
• 10 Day Avg. Volume: 8,947
• 30 Day Avg. Volume: 8,047
• PEG Ratio: 4.06
• Price to Book (P/B): 11.83
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -69.33
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €79.00
• Price Target Upside: 68.62% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 66 Neutral
• Price Target: €55.00 ▲(17.40%Upside)

PharmaNutra SpA's strong financial performance is a key factor in its overall score, reflecting solid growth and profitability. However, technical indicators suggest cautious market sentiment, and the stock's valuation is relatively high, limiting its attractiveness. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Financial Performance

PharmaNutra delivered a solid set of FY-24 results, with some key projects yielding initial contribution following prior investments and cash flow generation far exceeding expectations.

International Expansion

International operations remain the key growth driver, with PharmaNutra now present in 92 countries.

Market Position

Strong international performance contributed to an 11.2% year-over-year increase in net revenues, with Sideral® confirming its market leadership in Italy.

Negative Factors

Earnings Forecast

Expected tangible results from PHN USA in H2 2025 are below expectations, affecting revenue projections.

Margins

Significant investments in new initiatives are expected to lead to a slight reduction in margins over the next two years.

Profitability

As in recent quarters, investments in new business units slightly weighed on profitability.

PharmaNutra SpA Business Overview & Revenue Model

Company Description

Pharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, rest of Europe, the Middle East, Far East, and internationally. The company also produces and markets pharmaceuticals, medical devices, OTC products, and nutraceuticals for pediatric sector; and produces and distributes raw materials and active ingredients for the food, pharmaceutical, and food supplement industries. Its products primarily include SiderAL, SiderAL Forte, SiderAL Folic, Cardio SiderAL, SiderAL Med, Cetilar Crema, Cetilar Patch, Tape, ApportAL, UltraMag, Gestalys DHA, Novomega, Bonecal, and DiKappa 2. The company distributes and sells its products through sales representatives, wholesalers, pharmacies, and para-pharmacies. Pharmanutra S.p.A. was founded in 2003 and is based in Pisa, Italy.

How the Company Makes Money

PharmaNutra SpA generates revenue primarily through the sale of its nutritional supplements and medical devices. The company leverages a robust distribution network to market its products both domestically and internationally. Key revenue streams include direct sales to healthcare providers, pharmacies, and through partnerships with other pharmaceutical companies for broader distribution. Strategic collaborations and licensing agreements also play a significant role in expanding its market reach and driving sales growth.

PharmaNutra SpA Financial Statement Overview

Summary

PharmaNutra SpA exhibits robust financial health characterized by strong revenue growth, efficient cost management, and solid profitability margins. The balance sheet reflects stability with moderate leverage and effective equity utilization. Cash flow metrics indicate improved liquidity and cash generation capabilities.

Income Statement

PharmaNutra SpA has demonstrated robust revenue growth with a 15.6% increase from 2023 to 2024, complemented by strong gross profit and net profit margins. The gross profit margin for 2024 is 70.9%, reflecting efficient production operations. The net profit margin stands at 14.2%, indicating sound profitability. EBIT and EBITDA margins are also healthy at 23.4% and 27.5% respectively, showcasing effective cost management and operational efficiency.

Balance Sheet

The company maintains a stable financial position with a debt-to-equity ratio of 0.39, indicating moderate leverage. Return on equity is solid at 26.7%, reflecting effective use of shareholder funds. The equity ratio of 52.9% suggests a strong capital structure and financial stability, though careful monitoring of debt levels is advised to mitigate potential risks.

Cash Flow

PharmaNutra SpA shows a significant improvement in free cash flow, with a transition from negative to positive values year-over-year, indicating enhanced cash generation capabilities. The operating cash flow to net income ratio of 1.23 suggests healthy cash conversion efficiency. The free cash flow to net income ratio is also positive at 0.98, highlighting strong cash flow management.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	116.79M	101.03M	83.39M	68.58M	58.48M
Gross Profit	82.79M	48.95M	30.17M	25.33M	21.30M
EBITDA	32.01M	26.53M	24.61M	19.30M	15.10M
Net Income	16.61M	12.83M	15.05M	13.77M	14.07M
Balance Sheet
Total Assets	117.47M	112.44M	100.16M	71.36M	51.71M
Cash, Cash Equivalents and Short-Term Investments	29.10M	25.12M	26.86M	33.94M	20.80M
Total Debt	24.27M	28.02M	17.73M	6.35M	1.66M
Total Liabilities	55.27M	58.04M	49.21M	26.27M	13.98M
Stockholders Equity	62.16M	54.41M	50.95M	45.08M	37.73M
Cash Flow
Free Cash Flow	16.25M	-1.16M	-8.69M	15.43M	10.46M
Operating Cash Flow	20.50M	12.09M	14.47M	20.41M	11.79M
Investing Cash Flow	-2.21M	-14.70M	-23.71M	-5.54M	-598.00K
Financing Cash Flow	-21.59M	-516.00K	1.89M	-1.92M	-4.73M

PharmaNutra SpA Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 46.85
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:PHN, the sentiment is Negative. The current price of 46.85 is below the 20-day moving average (MA) of 48.36, below the 50-day MA of 50.32, and below the 200-day MA of 52.34, indicating a bearish trend. The MACD of -1.33 indicates Positive momentum. The RSI at 34.09 is Neutral, neither overbought nor oversold. The STOCH value of 28.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IT:PHN.

PharmaNutra SpA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PHN	66 Neutral	€453.55M	27.42		1.82%	17.78%	63.72%
Sector *	59 Neutral	£5.95B	9.22	-57.69%	4.67%	15.15%	-8.16%
78Q		€614.10M	18.51	39.51%	―	―	―
COSMO		€18.31M	―		―	―	―
TALEA		€36.49M	―		―	―	―
ERFO		€11.68M	34.69		4.74%	―	―
SVS		€42.96M	7.66		3.11%	―	―